Currently, a humanized anti-BTLA (JS004) designed to target HVEM/BTLA is undergoing a clinical trial of phase I for advanced solid tumors, including gastric adenocarcinoma, esophageal squamous cell carcinoma, liver, cervical, and MSI-H colorectal cancers. Here, BTLA is linked to colorectal cancer.